Tests prucalopride for thinking and memory problems in schizophrenia
Tests prucalopride, added to usual antipsychotics, in people with schizophrenia.
Plain-language title generated from the registry record
Registry title: Prucalopride for Cognitive Functioning in Schizophrenia
Key facts
- Where
- Mangalore, IndiaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 55 with schizophrenia who are clinically stable on their antipsychotic medicine. It tests prucalopride 1 mg for 4 weeks on thinking skills.
- Age
- 18 to 55 years
- Sex
- Women and men can join.
- Disease stage
- Schizophrenia diagnosed by DSM 5 criteria, ill for at least one year, and clinically stable.
- Earlier treatment
- Must have been on a stable dose of treatment for at least 3 months before joining. Must not already be taking prucalopride.
Main reasons for not taking part
- Acute symptoms and not able to cooperate with the assessments
- Other psychiatric illness, including mood disorders and substance use disorders (tobacco is allowed)
- Intellectual disability, head injury, or sensory impairments
- Pregnant or breastfeeding women
- Current suicidal thoughts, intention or attempts
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT06474286, who can take part
Where in India
- K S Hegde Medical Academy,Mangalore, IndiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Pittsburgh
- Trial code
- NCT06474286
- Record updated
- 17 September 2026
- Original description
A core component of schizophrenia is neurocognitive impairment. The cognitive deficits are prominently seen in memory, attention, working memory, problem solving, processing speed and social cognition. Atypical antipsychotics continue to be the mainstay of treatment in schizophrenia.Read full original descriptionShow less
A Pilot Study to Assess the Effect of Prucalopride on Cognitive Functioning in Patients With Schizophrenia
A core component of schizophrenia is neurocognitive impairment. The cognitive deficits are prominently seen in memory, attention, working memory, problem solving, processing speed and social cognition. Atypical antipsychotics continue to be the mainstay of treatment in schizophrenia.
Promising areas for future research include search for new compounds for cognition enhancement. Prucalopride, a highly selective 5HT4 receptor agonist is a potential drug and its effect on cognition in patients with schizophrenia needs to be studied.
An open label, pilot study involving 34 patients with schizophrenia diagnosed as per DSM 5 criteria. The participants will receive Tab. Prucalopride one milligram (1 mg) for a duration of four weeks along with their existing treatment regimen with antipsychotics.
Assessments includes PANSS and BACS at baseline and at the end of 4 weeks. The effect of prucalopride on cognitive functioning in patients with schizophrenia is studied.
Inclusion: Diagnosed as schizophrenia by DSM 5 criteria using Structured Clinical Interview for DSM disorders; Age between 18 to 55 years; A minimum of one year of duration of illness; Clinically stable with a stable therapeutic dose for at least 3 months prior to the recruitment; Participants who can read and write English or Kannada.
Exclusion: Participants administered MECT (modified electroconvulsive therapy); Use of concomitant herbal remedies, alternative medicines; Co morbid with other psychiatric illness including mood disorders and substance use disorders except tobacco; Participants already diagnosed with Intellectual Disability Disorder, head injury; Diagnosed with gastrointestinal disorders like Ulcerative colitis, Crohn's disease, Intestinal ulcers; Current history of suicidal ideation, intention or attempts; Participants who are acutely symptomatic and are uncooperative for assessments; Participants with sensory impairments; Use of Donepezil, Rivastigmine, Memantine, Benzodiazepines; Participants already on prucalopride; Participants with contraindications to prucalopride; Women who are pregnant or lactating.